Posted by AGORACOM-JC
at 2:44 PM on Wednesday, October 14th, 2020
SPONSOR: Avicanna (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. Learn More.
CBD Skin Care Market Is Booming Worldwide with Strong Growth
Multi-functional attributes such as powerful antioxidants and anti-inflammatory properties of Cannabidiol (CBD) driving the demand for CBD skincare products. It is useful in the treatment of eczema, psoriasis, and acne. The market has high growth prospects owing to rising awareness about skin healing properties of CBD and growing preference for sustainable skincare products. Moreover, the growing online distribution channels for CBD skincare products expected to drive the product demand during the forecasted period.This growth is primarily driven by Rising Awareness about Skin Healing Properties of CBD and Growing Preference for Sustainable Skin Care Products.
AMA Research have added latest edition of survey study on CBD Skin Care Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. The research study provides estimates for CBD Skin Care Forecast till 2025*.
Important Features that are under offering & key highlights of the report:
1) How Study Have Considered the Impact of COVID-19 / Economic Slowdown of 2020 ?
Analyst at AMA are constantly gathering and conducting survey with opinion leaders and Industry experts from various region to minutely understand impact on growth as well as local reforms to evaluate study and market estimates. Due to lockdown different online medium and procedures are followed like Survey Monkey, LinkedIn Connections, and Email reach and industry forum to established industry viewpoint to garner rich insights for study. A special chapter in the study presents Impact Analysis of COVID-19 on CBD Skin Care Market along with tables and graphs related to various country and segments showcasing impact on growth trends.
2) Can list of players be customize according to targeted regional geographies to match business objective?
Considering heat map analysis and based on market buzz or voice the profiled list of companies in the report are ” Kiehl’s LLC (United States), Cannuka LLC (United States), Elixinol Global Limited (Australia), Medical Marijuana Inc. (United States), Endoca LL (Netherland), Lord Jones (United States), Kapu Maku LLC (United States), Leef Organics (United States), FAB CBD (United States), IRIE CBD (United States) and Kazmira (United States)”. Yes, further list of players can also be customized as per your requirement keeping in mind your areas of interest and adding local emerging players and leaders from targeted geography.
3) Can Market be broken down by different set of application and types?
Additional segmentation / Market breakdown is possible subject to data availability, feasibility and depending upon timeline and toughness of survey. However a detailed requirement needs to be prepared before making any final confirmation.
** 3+ Additional country of your interest can be included at no added cost feasibility test would be conducted by Analyst team of AMA based on the requirement shared and accordingly deliverable time will also be disclosed.
Market Drivers
Rising Awareness about Skin Healing Properties of CBD
Growing Preference for Sustainable Skin Care Products
Market Trend
Growing Acceptance of CBD Products
Restraints
Stringent Government Regulations Regarding CBD Product Manufacturing
Posted by AGORACOM-JC
at 3:39 PM on Thursday, October 8th, 2020
Despite the collapse of marijuana and cannabis related stocks in the last 18 months, there is no denying that Cannabis related products are going to go through a paradigm shifting, parabolic growth stage around the world over this decade for the following reasons:
Cannabis legalization is gaining momentum around the world.
Momentum is primarily driven by the realization that cannabis may have a range of medicinal, therapeutic and wellness applications.
It is the most widely cultivated, consumed and trafficked drug worldwide (United Nations Office on Drugs and Crime).
So what is this going to translate into?
The global cannabis market size was valued at $US 10.6 Billion in 2018 and is projected to reach $97.5 Billion by the end of 2026, a CAGR of 32.92%(Fortune Business Insights)
WHY WILL THIS TIME BE DIFFERENT?
Big promises, big IR budgets, big hype …. Big Letdown.
That pretty much sums up the last cycle of Cannabis related companies that focused on speed, stories and stock prices rather than the one simple but important thing they should have been doing – building a real business.
Investors will remember that the same thing happened during the dot-com era. As with the cannabis collapse over the last 18 months, what followed back in 2000 was a long period of mourning in which many investors had sworn off tech stocks, just as they have with cannabis stocks today.
But it wasn’t long until tech investors dusted themselves off and realized tech was here to stay – but this time they were only going to focus on real companies with real businesses. What we got was Amazon, Google, Linkedin, Facebook and then the rest was history.
The same thing is about to happen to the Cannabis sector
Meet the 8 new horsemen of the next leadership group that are firing on all cylinders (in alphabetical order).
Avicanna (AVCN :TSX) (AVCN : OTCQX) ( 0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.
When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:
1. The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year. These are the only known CBD cosmetics backed by clinical trials.
2. Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain. In addition, the company recently received certification and authorization for the sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia.
3. Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.
For more information about the company, please check out the Avicanna HUB on AGORACOM.
Empower (CBDT: CSE) (EPWCF:OTCQB) (8EC:Frankfurt) is a vertically integrated, multi-state operator of medical clinics with a database of over 165,000 patients, a database that almost every medical cannabis and CBD company would kill for … but then these numbers recently came in for the first two quarters to further cement Empower as a leader:
PatientVisits
Q1 + 377% To 5,717
Q2 + 56% To 6,696
Revenues $USD
Q1 + 416% To $790,000 (NO COVID)
Q2 + 56% To $923.000
TOTAL Q1 AND Q2
REVENUE $1.7M vs $745K = + 130%
PATIENTS 12,400 vs 5,500 = + 125%
NET LOSS $920K vs 1.85M = – 50%
Empower has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019.
BONUS – The Company’s physician staffed clinics have are also generating significant revenue and growth from the COVID-19 pandemic as follows:
Increased CBD treatments from patients suffering increased anxiety;
Testing for individuals and families
Testing for local businesses and employees
Testing for enterprise level organizations across the country
At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY
Oh, and did we mention that CEO Steven McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch? We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never. Which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.
For more information about the company, please check out the Empower HUB on AGORACOM.
Harborside (HBOR: CSE), (HSDEF: OTCQX) has generated over $400,000,000 (NOT a typo) since its inception in 2006. We thought that would get your attention.
What Do They Do?
HBOR is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments:
1. Retail Dispensaries
2. Wholesale
3. Cultivation and Processing
HIGHLIGHTS
Founded in 2006. One of the oldest and most respected cannabis retailers in California
Awarded one of the first six medical cannabis licenses in the USA
Operations have generated over $400M in cumulative sales since inception
Retail operations command 3% of California’s entire retail market
2020 Financials (Q1 + Q2)
○ Revenues $30,800,000
○ Gross Profit $14,000,000
○ EBITDA $1,100,000
Expected to generate approximately $62M – $65M in sales in 2020
Operate California’s only drive-through dispensary
Over 1,300 customers per day in Q2
Oakland dispensary is one of the largest retail cannabis locations in the world
2020E Guidance
~$44M Retail Revenue
~$21M Wholesale Revenue
~$62M – ~65M Total Revenue
For more information about the company, please check out the Harborside Inc hub on AGORACOM.
Hollister Biosciences Inc. (HOLL:CSE) (HSTRF:OTC) (HOB: FRANKFURT) is a multi-state cannabis company with products in 230 dispensaries throughout California and over 80 dispensaries throughout Arizona, translating into the following great success:
Revenues $USD
Q1 +317% YoY to $862,000
Q2 +3685% YoY to $8,500,000
TOTAL Q1 AND Q2
REVENUE $9.4M vs $428K = + 2096%
GROSS PROFIT $1.2M vs ($133K) = + 1002%
In addition to organic sales, Hollister has several high-level partnerships that demonstrate how trusted the Company is within the industry, including:
Hollister is also the creator of California’s most hash-infused pre-roll HashBone
For more information about the company, please check out the Hollister Biosciences Inc. hub on AGORACOM.
Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.
3 Fully Operating Divisions For Investor Diversification
Innocan has 3 fully operating divisions to address the market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.
PHARMACEUTICAL – THE GUIDED MISSILE – Revolutionary technology targeting lungs infected with coronavirus or other viral infections.
CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.
OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.
Global Manufacturing / Distribution Agreements
Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)
Superior Management Team
In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself. The InnoCan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:
Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.
Together they have built one of the most formidable teams in the small cap cannabis world
For more information about the company, please check out the Innocan Pharma Corporation hub on AGORACOM.
Spyder Cannabis Inc. (SPDR :TSXV) is a Cannabis, Vape and CBD retailer with three retail business units.
SALE OF CANNABIS PRODUCTS – The Company has TWO cannabis dispensaries currently in operation. The first being a location in Calgary, Alberta and the second in Niagara Falls. Both dispensaries are located in busy commercial hubs. The management team is currently evaluating several additional locations in both Alberta and Ontario where it intends to expand the Spyder Cannabis brand’s footprint.
SALE OF HEMP CBD (US) Company is also pursuing the sale of Hemp based CBD products from locations in the USA.
SMOKING CESSATION PRODUCTS IN ONTARIO The company sells electronic cigarettes, E-juice and accessories for the “vape” business from five Canadian retail locations; Woodbridge, Scarborough, Pickering, Niagara Falls and Burlington, Ontario. Spyder has established itself as a savvy retailer.
For more information about the company, please check out the Spyder Cannabis hub on AGORACOM.
Thoughtful Brands, Inc. (TBI: CSE)( 1WZ1: FWB)( PEMTF: OTCQB) is a global natural health products and eCommerce technology company that is operating at full throttle.
Acquired eCommerce retailers with combined total sales of approximately $29,000,000 with an EBITDA of approximately 12.5%.
Current customer base of over 200,000 customers with additional leads of over 600,000 potential new customers
Enhanced eCommernce solution through Unified Funding’s software which facilitated over $350 million in consumer transactions (CAD $93.8 million) in 2019 from more than one million paying customers.
Low-cost production will be vertically integrated into retail brands to achieve up to 20x margin increase.
We’ll let these revenue numbers speak for themselves.
August 2020 CAD $3,809,000
July 2020 CAD $2,340,000
June 2020 CAD $2,712,000
The above represents an increase of 19%, over the same period in 2019.
QUARTERLY REVENUE $CAD
Q1 $7,600,000 Growth
Q2 $12,800,000 Growth
TOTAL Q1 AND Q2
REVENUE $20,400,000
GROSS PROFIT $2,154,357
The company has its sights set on European expansion through a joint venture with Franchise Cannabis Corp. The company will now sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the UK, utilizing its eCommerce platform.
The company also completed acquisition of Verrian, which owns and operates a 110,000-square foot pharmaceutical manufacturing facility in Radebuel, Germany. This acquisition will assist the company in tapping into the burgeoning market for psychedelics as Verrian specializes in developing psychedelic derived medicines for treatments for addictions, including opioids and alcohol.
For more information about the company, please check out the Thoughtful Brands hub on AGORACOM.
TransCanna (TCAN:CSE) (TH8:FSE) owns a 196,000 square foot cannabis Facility, the largest known fully licensed cannabis facility in California.
CAD$24.9M Revenue Run Rate from 10,000 sq.ft test facility
CAD $90M Annual Revenue expected from first full year of production at Fully Licensed Daly Street Facility.
Acquired two California companies,
High-end award winning edible producer Soldaze
Premium indoor cultivator and distributer Lyfted Farms
Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
2019 California Cannabis sales over $3B, industry currently fragmented
Direct to dispensary model, cutting out the middleman
REVENUES $CAD
Q1 $906,000
Q2 $4,300,000
TOTAL Q1 AND Q2
REVENUE $5,206,000
GROSS MARGIN $1,920,000
For more information about the company, please check out the TransCanna hub on AGORACOM.
Thanks for reading and discovering these great small cap cannabis companies. Please be sure to visit the AGORACOM Small Cap Cannabis Gateway often to stay up to date with new companies at:
Avicanna is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. LEARN MORE.
Posted by AGORACOM-JC
at 11:05 AM on Wednesday, October 7th, 2020
SPONSOR: Avicanna (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. Learn More.
Growing Adoption of CBD Pharmaceutical Grade and Wellness Products Having Healthy Impact on Market Growth
Global CBD and CBD oil market revenues are projected to continue to rise significantly in the coming years
Increasing consumer preference for various cannabidiol infused products such as capsules, cannabis oil, beverages, beauty and skincare products, gummies, and dog treats is further anticipated to drive the CBD oil and CBD consumer health market
PALM BEACH, Fla., Oct. 1, 2020– The global CBD and CBD oil market revenues are projected to continue to rise significantly in the coming years. Increasing consumer preference for various cannabidiol infused products such as capsules, cannabis oil, beverages, beauty and skincare products, gummies, and dog treats is further anticipated to drive the CBD oil and CBD consumer health market. Cannabidiol can enter the body in several ways such as vaping, ingesting, smoking, and through the skin. Growing adoption of cannabidiol to manufacture medical drugs and personal care products in states where cannabis is legal is positively impacting the market growth. The legalization of cannabis-based products has provided a remarkable opportunity for the end-user industries to expand. The growing number of research activities, increasing awareness regarding synthetic cannabidiol, and rising strategic investments by companies are expected to contribute to the overall growth through 2027.
Posted by AGORACOM-JC
at 8:00 AM on Tuesday, September 29th, 2020
Entered into an agreement whereby Avicanna will develop certain hemp-derived cannabinoid-based products including sublingual and sustained released tablets intended for the sleep market for a US distributor
The agreement showcases Avicanna’s expertise in cannabinoid product development and drug delivery across several delivery mechanisms
TORONTO , Sept 29, 2020 – Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that it has entered into an agreement (the ” Agreement “) whereby Avicanna will develop certain hemp-derived cannabinoid-based products including sublingual and sustained released tablets intended for the sleep market ( the ” Development Products “) for a US distributor (” USCo “).
Under the Agreement, Avicanna will develop the intellectual property (the ” Development IP “) that forms the basis of the Development Products for a development fee. Based on the Development IP, USCo will manufacture, distribute and market the Development Products and will pay Avicanna an ongoing royalty payment based on the gross revenue of the Development Products. Avicanna will also have the opportunity to supply the cannabinoids for the manufacture of the Development Products.
Aras Azadian , CEO of Avicanna, commented: “We continue to demonstrate our advanced capabilities in formulation development, optimization and drug delivery for the cannabinoid industry which has utilities across CPG, adult use, medical and pharmaceutical applications. We also take pride in being selected by world class partners to provide our technology and intellectual property which in turn provides additional sources of revenue in the form of royalties.”
To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.
About Avicanna
Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.
Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:
Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.
With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.
Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.
Stay Connected
For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email at [email protected] .
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of Avicanna or USCo to perform under the Agreement, the ability of the Company to develop the Development IP to form the basis of the Development Products, the ability of USCo to manufacture and distribute the Development Products, and the ability of the Company to supply the cannabinoids to be used in the manufacture of the Development Products. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, the delay or failure to receive regulatory approvals, and the risk factors set out in the Company’s annual information form dated April 15, 2020 , filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .
The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical.
CONSUMER RETAIL – COSMETICS
The Only Known CBD Cosmetics Backed By Clinical Trials
Full Line Of High End CBD Based Skin Care Products
Already Commercializing In Colombia
Global Distribution In H2 2020 In United States, Europe and Canada
Canadian Distribution Through Shoppers Drug Mart
MEDICAL CANNABIS
Medical Cannabis 2.0 – Superior Products To Products Currently On The Market
Evidence Backed Medical Cannabis So Doctors Can Prescribe With Confidence
Full Launch Across Canada Immanent
Exclusive Distribution Through Online Store Of Shoppers Drug Mart
RHO Phyto “Micro Drop” oil formulations are the first of the RHO Phyto formulary of advanced medical cannabis products available for patients and health care practitioners
Obtained GPP certification and authorization by INVIMA for the compounding and sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia
Global Distribution Through US, U.K, Australia and Canada In H2 2020
PHARMACEUTICALS
A Full Pipeline Of Pharmaceuticals In Various Stages Of Trials To Address Dermatology, Psychiatry, Neurology, Pain and Oncology
3 Products Already As Far As PHASE 2
CULTIVATION
500,000 Sq Ft Of Low Cost and USDA certified Organic Cannabis Cultivation In Colombia
First Ever Export Of Feminized Hemp Seeds From Colombia (To United States). 7,000,000 Seeds For $380,000
Additional 75,000,000 Seeds Available For Export In Several Pending Transactions
Posted by AGORACOM-JC
at 9:27 AM on Monday, September 21st, 2020
Avicanna Rapid Act Spray
RHO Phyto™ Rapid Act Sprays are now available nationwide in high ratios of CBD to THC and are designed for rapid absorption and with lemon-mint flavour on the Medical Cannabis by Shoppers™ portal.
The Rapid Act Sprays are also available for the Medical Cannabis Real World Evidence Studies (MC-RWE) conducted by the University Health Network in partnerships with Medical Cannabis by Shoppers along side RHO Phyto’s Micro Drop Oil formulations.
TORONTO , Sept. 21, 2020 – Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that its advanced RHO Phyto Rapid Act Sprays are now officially available nationwide in Canada on the Medical Cannabis by Shoppers (” Shoppers “) portal, as well as through the Medical Cannabis Real-World Evidence Study at the University Health Network.
Avicanna’s RHO Phyto product line is now commercially available after years of research and development through collaborations with world class academic and clinical organizations. The development of RHO Phyto products has focused on the key properties in drug development that health care providers seek when recommending a medical product to their patients such as formulation stability for consistent dosing, enhanced absorption and a range of onset times.
The Rapid Act Spray is a sublingual spray and is among the second set of Avicanna’s RHO Phyto products available for purchase through Shoppers. The sublingual sprays bypass first-pass metabolism and are quickly absorbed in the mucosal lining under the tongue. The RHO Phyto Rapid Act Spray provides an alternative delivery form to the RHO Phyto Micro Drops (also available for sale through Shoppers) which are absorbed through the oral route. The RHO Phyto Rapid Act Sprays have been formulated with specific ingredients that enhance absorption and the onset time of cannabinoids across the mucous membrane beneath the tongue. The lemon-mint flavoured sprays will be available in 10:20 CBD and 2:40 (w/w) THC to CBD ratios.
Dr. Justin Grant , Avicanna’s Executive Vice President of Scientific Affairs, commented, “The RHO Phyto Rapid Act Sprays are designed for faster onset and can be used in acute conditions where patients seek faster relief. The sublingual sprays can also be used to supplement slower and longer acting products, such as the RHO Phyto Micro Drop, when occasional higher doses may be required. Sublingual administration provides an alternative to the potentially harmful effects of consuming inhalation products.”
In August 2020 , Avicanna launched its blood orange flavoured RHO Phyto Micro Drop 2:50 CBD and Micro Drop 5:20 CBD. In the coming months, Avicanna will be launching its much-anticipated RHO Phyto Deep Tissue Gel, Daily Cream and Simple Dose Capsules. To ensure batch-to-batch consistency and high-quality products, these formulations are manufactured at MediPharm Labs Inc, a Good Manufacturing Practices (” GMP “) certified facility. In addition to strict GMP manufacturing, all RHO Phyto products undergo GMP-level analytical testing by Sigma Analytical Services Inc. and use blockchain technology developed by TruTrace Technologies Inc. to manage, track and trace each step of the supply chain.
Detailed guidelines outlining dosing and titration for Health Care Practitioners (” HCPs “) and patients is available on the RHO Phyto website at www.rhophyto.com . In addition, the Avicanna Academy includes additional product information for patients, frequently asked questions, and a recording of Avicanna’s 3rd annual symposium which was hosted virtually in partnership with Shoppers on July 21, 2020. For more information visit https://www.avicanna.com/the-avicanna-academy/ .
The Company has also re-branded and re-launched its subsidiary, My Cannabis Clinic (formerly known as My Cannabis), which specializes in assisting patients to gain access to medical cannabis and cannabinoid-based products for medical use. My Cannabis Clinic is devoted to providing HCPs and patients with the support and education needed for medical cannabis use. My Cannabis Clinic believes in providing quality care to patients and providing education on the considerations and potential benefits that cannabis has to offer for medical use. Information about My Cannabis Clinic can be found at https://mycannabisclinic.org/ .
About Avicanna
Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.
Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:
Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.
With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.
Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email at [email protected] .
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the RHO Phyto Rapid Act Sprays to be used in acute conditions where patients seek faster relief, the ability of the RHO Phyto Rapid Act Sprays to be used to supplement slower and longer acting products, the ability of the Company launching the RHO Phyto Deep Tissue Gel, Daily Cream and Simple Dose Capsules , the ability of My Cannabis Clinic to provide HCPs and patients with the support and education needed for medical cannabis use, and that there is a benefit to using cannabis for medical purposes. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020 , filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .
The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Posted by AGORACOM-JC
at 7:52 AM on Monday, September 14th, 2020
Authorized cannabinoid products will be available to the medical community and patients in early Q4 2020 including Avicanna’s advanced oral, sublingual, and topical formulations branded and sold as RHO Phyto™ in Canada and other markets.
This is the first ever compound pharmacy in Colombia authorized to specialize only in the production of cannabinoid formulations and the first authorized to offer topicals.
This is the final step in Avicanna’s fully integrated seed to patient business model in Colombia, which includes cultivation, extraction and manufacturing of pharmaceutical products for the emerging medical market with the 50 million people.
TORONTO, Sept. 14, 2020 – Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces that through its wholly owned subsidiary Avicanna LATAM S.A.S. (“Avicanna LATAM“), the Company’s pharmacy in Bogota has been certified with Good Preparation Practices (“GPP“) and authorized by the National Institute for Drug and Food Surveillance (“INVIMA“) for the sale of compounded pharmaceutical products to service medical prescriptions of individual patients in Colombia.
“We are thrilled to be able to offer our pharmaceutical preparations to the Colombian medical and patient communities. While the medical cannabis market in Colombia is still in its infancy, we are committed to educating both physicians and the medical community of the benefits and potential risks of cannabinoid-based medicine for their patients. We are leveraging years of learning and extensive research and development allowing us to provide the Colombian population with standardized and advanced medical solutions.” Aras Azadian CEO, Avicanna Inc.
The GPP authorization permits Avicanna LATAM to manufacture its line of advanced cannabinoid formulations including oral, sublingual, and topical preparations to service individual prescriptions issued by qualified medical professionals such as doctors, hospitals, and third-party independent clinics. The unique cannabinoid formulations are branded as RHO Phyto™ in mature cannabis markets, such as Canada, and are poised to set the standard in Latin America by offering products with years of extensive research and development manufactured with world-class quality standards. All the formulations have been optimized for consistent delivery and increased absorption and are designed to maintain the stability of the cannabinoids over the course of treatment.
The cannabinoids used in the preparation of these final products are locally-sourced from Avicanna’s majority owned subsidiaries Santa Marta Golden Hemp S.A.S. (“SMGH”) and Sativa Nativa S.A.S. (“SN“) allowing for full control and adherence to the highest quality standards along the entire value chain from seed to finished product. The commercialization strategy for the launch of these medical cannabis products includes education and training of health care professionals and partnerships with third-party hospitals and clinics which have been cultivated over the past few years.
Lucas Nosiglia, President of Avicanna LATAM commented “We are proud to be one of the first companies to offer the Colombian market with these unique product formulations that may address a variety of medical conditions and treat patients across in Colombia. Furthermore, we are providing Colombians with the combination of Avicanna’s advanced formulations and our own organic and sustainably cultivated cannabis from the foothills of the Sierra Nevada in Santa Marta.”
About Avicanna
Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.
Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:
Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.
With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.
Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.
Stay Connected
For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements with respect to the ability of the Company to provide the Colombian population with standardized and advanced medical solutions, the ability of Avicanna LATAM to manufacture its line of advanced cannabinoid formulations to service individual prescriptions issued by qualified medical professionals, the Company’s ability to set the standard in Latin America by offering products with years of extensive research and development manufactured with world-class quality standards, the ability of the unique formulations to maintain the stability of the cannabinoids over the course of treatment, the ability of the Company to source the cannabinoids for the manufacture of the medical cannabis products from SMGH and SN, the ability of the product formulations to address specific medical conditions, and the ability of SMGH and SN to continue to cultivate organic and sustainable cannabis. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com.
The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Tags: cannabinoids, CSE, Marijuana, Medical Cannabis by Shoppers, Rho Phyto, stocks Posted in Avicanna Inc., Featured | Comments Off on Avicanna’s $AVCN.ca subsidiary obtains GPP certification and authorization by INVIMA for the compounding and sale of pharmaceutical #cannabinoid products with medical prescriptions in Colombia $WEED.ca $TLRY $HARV.ca
When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical.
CONSUMER RETAIL – COSMETICS
The Only Known CBD Cosmetics Backed By Clinical Trials
Full Line Of High End CBD Based Skin Care Products
Already Commercializing In Colombia
Global Distribution In H2 2020 In United States, Europe and Canada
Canadian Distribution Through Shoppers Drug Mart
MEDICAL CANNABIS
Medical Cannabis 2.0 – Superior Products To Products Currently On The Market
Evidence Backed Medical Cannabis So Doctors Can Prescribe With Confidence
Full Launch Across Canada Immanent
Exclusive Distribution Through Online Store Of Shoppers Drug Mart
RHO Phyto “Micro Drop” oil formulations are the first of the RHO Phyto formulary of advanced medical cannabis products available for patients and health care practitioners
Global Distribution Through US, U.K, Australia, Colombia and Canada In H2 2020
PHARMACEUTICALS
A Full Pipeline Of Pharmaceuticals In Various Stages Of Trials To Address Dermatology, Psychiatry, Neurology, Pain and Oncology
3 Products Already As Far As PHASE 2
CULTIVATION
500,000 Sq Ft Of Low Cost and USDA certified Organic Cannabis Cultivation In Colombia
First Ever Export Of Feminized Hemp Seeds From Colombia (To United States). 7,000,000 Seeds For $380,000
Additional 75,000,000 Seeds Available For Export In Several Pending Transactions
